Navidea biopharmaceuticals announces submission of formal type b meeting request with fda and launch of nav3-32 phase 2b trial in rheumatoid arthritis

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the company has submitted its formal type b meeting request to the fda. the fda has granted the type b meeting and has requested submission of the briefing book. the fda will now review the company's formal briefing documents containing results from the nav
NAVB Ratings Summary
NAVB Quant Ranking